Autoantibodies to ADAMTS13 in human immunodeficiency virus‐associated thrombotic thrombocytopenic purpura

Documenti analoghi

• The prevalence of hepatitis B virus, human T‐lymphotropic virus and human immunodeficiency virus in patients receiving blood transfusions in South Africa
  di: Reynier J. Willemse, et al.
  Pubblicazione: (2024)
• Risk factors for incident human immunodeficiency virus infection in South African blood donors
  di: Avril Swarts, et al.
  Pubblicazione: (2025)
• Comment on ‘Comparing specificity and seroconversion sensitivity among major blood screening assays for human immunodeficiency virus and viral hepatitis’
  di: Ramune Sepetiene, et al.
  Pubblicazione: (2026)
• Has the switch to sexual risk behaviour screening impacted deferrals for pre‐ and post‐exposure prophylaxis therapy for human immunodeficiency virus?
  di: Mindy Goldman, et al.
  Pubblicazione: (2024)
• Trends in donor infection profiles and residual risks of transfusion‐transmitted human immunodeficiency virus, hepatitis C virus and hepatitis B virus after the implementation of universal mini‐pool nucleic acid testing in Taiwan
  di: Wen‐Jie Liu, et al.
  Pubblicazione: (2025)